Xbrane Biopharma AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
May. 10 | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
May. 02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
Sales 2024 * | 344M 31.69M | Sales 2025 * | 680M 62.74M | Capitalization | 351M 32.37M |
---|---|---|---|---|---|
Net income 2024 * | -186M -17.15M | Net income 2025 * | 104M 9.59M | EV / Sales 2024 * | 0.94 x |
Net cash position 2024 * | 28.17M 2.6M | Net Debt 2025 * | 116M 10.68M | EV / Sales 2025 * | 0.69 x |
P/E ratio 2024 * |
-1.7
x | P/E ratio 2025 * |
4.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
Latest transcript on Xbrane Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 19-12-31 | |
Eva Nilsagård
BRD | Director/Board Member | 60 | 19-05-15 |
Kirsti Gjellan
BRD | Director/Board Member | 61 | 22-05-04 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |